zenith Study Design

Active, enrolling

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH)[1-2]

Study Population

Adult patients with uncontrolled hypertension and high CV risk

Key Inclusion Criteria

- 18 years or older for patients with established CVD[a]
- 55 years or older for patients with high risk for CVD
- Receiving stable therapy with at least 2 standard of care antihypertensive medications, 1 of which must be a thiazide, thiazide-like, or loop diuretic

Key Exclusion Criteria

- Known history of secondary hypertension
- Symptomatic orthostatic hypotension
- ALT or AST >3 x ULN
- Total serum bilirubin >1.5 x ULN
- INR >1.5
- Serum potassium >4.8 mEq/L
- eGFR <30 mL/min/1.73 m2



Primary Endpoint

- Time to first occurrence of a composite of CV death, nonfatal MI, nonfatal stroke, or HF event[b]

Key Secondary Endpoints

- Change from baseline at Month 6 in mean seated office SBP
- Time to first occurrence of a composite of CV death, nonfatal MI, or nonfatal stroke
- Composite of CV death and total HF events
- Time to first occurrence of a composite of CV death, nonfatal MI, nonfatal stroke, or coronary revascularization
- Time to all-cause death

Safety Endpoint

- Frequency of AEs

[a]CVD response defined as coronary, cerebrovascular, or peripheral artery disease. [b]HF event defined as hospitalization for HF or urgent HF visit. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ILN, international normalized ratio; MI, myocardial infarction; Q6M, every 6 months; SC, subcutaneous; ULN, upper limit of normal. 1. ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07181109 (Accessed July 30, 2026). 2. Pagidipati N, et al. European Society of Cardiology Congress, August 29-September 1, 2025, Madrid, Spain. Oral presentation.

Alnylam